Aytu BioPharma, Inc.
Every calculator, already run for AYTU
Open the full toolkit →You have the numbers on AYTU. Get the argument.
A written report on which of these readings actually decide the outcome for Aytu BioPharma, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
3 analysts covering AYTUAnalyst Price Target Disagreement for Aytu BioPharma, Inc.
Wall Street's bull case implies +587% from the current price; the bear case implies +232%. A 355% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for AYTU
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Aytu BioPharma, Inc.
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspe…
AYTU — frequently asked
Is AYTU a buy right now?
Wall Street's consensus rating on Aytu BioPharma, Inc. is none across 3 analysts, with a mean price target of $9.50 (+350% vs. the current $2.11). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Aytu BioPharma, Inc.?
Analysts covering Aytu BioPharma, Inc. (AYTU) range from a bear-case target of $7.00 to a bull-case high of $14.50, with a mean consensus target of $9.50 across 3 analysts. The spread of $7.50 (355% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Aytu BioPharma, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Aytu BioPharma, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full AYTU research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Aytu BioPharma, Inc., in minutes. 3 free reports included with every account — no credit card required.